TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17189464

Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery with post-operative rehabilitation
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Arthroplasty with post-operative rehabilitation
Number of subjects: 106
Study: 16039961

Group type: COMPARATOR
Intervention: Closed tracheal suction system (CTSS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Partially ventilated endotracheal suction method (PVETS)
Number of subjects: 15
Study: 12131981

Group type: COMPARATOR
Intervention: Placebo solution (mentholated deionized water)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate + 0.05% sodium fluoride
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.5% stevioside + 0.05% sodium fluoride (pH 3.4)
Number of subjects: 200
Study: 10613374

Group type: EXPERIMENTAL
Intervention: Tablet splitting using a tablet splitter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tablet splitting
Number of subjects: 0
Study: 8970693

Group type: EXPERIMENTAL
Intervention: 21 days of methadone detoxification
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: 90 days of methadone detoxification
Number of subjects: 1803
Study: 1747217

Group type: EXPERIMENTAL
Intervention: 1 g of elemental calcium in the form of oystershell electrolysate (AA calcium)
Number of subjects: 0
Study: 6186187

Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg/dose)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 47
Study: 30448094

Group type: EXPERIMENTAL
Intervention: Warmed crystalloid at 37°C
Number of subjects: 60

Group type: COMPARATOR
Intervention: Room temperature crystalloid
Number of subjects: 60
Study: 29674605

Group type: EXPERIMENTAL
Intervention: Brain training games (BTG) using Lumosity for 15 min per day, at least 7 days per week, for 3 weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Brain training games (BTG) using Lumosity
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (n=21)
Number of subjects: 51
Study: 26231286

Group type: EXPERIMENTAL
Intervention: Trans-obturator tape (TOT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 87
Study: 24679444

Group type: EXPERIMENTAL
Intervention: IAI 2 mg (IAI 2Q4)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 188
Study: 23017384

Group type: EXPERIMENTAL
Intervention: Ottawa Influenza Decision Aid (OIDA)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study: 20060571

Group type: EXPERIMENTAL
Intervention: Road traffic noise exposure (n=280, L(eq,24h)=67±2dB(A))
Number of subjects: 659

Group type: COMPARATOR
Intervention: Control group (n=379, L(eq,24h)=58.7±6dB(A))
Number of subjects: 659
Study: 17546842

Group type: EXPERIMENTAL
Intervention: Flaxseed flour (30 g/day, 5 g of alpha-linolenic acid)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (manioc flour)
Number of subjects: 24
Study: 16383055

Group type: EXPERIMENTAL
Intervention: Resin-based composite inlays (Paradigm, 3M ESPE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Porcelain inlays (Vita Mark II, Vita Zahnfabrik)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both materials (Resin-based composite and Porcelain)
Number of subjects: 80
Study: 12058009

Group type: EXPERIMENTAL
Intervention: Intensive treatment initiated in early adolescence
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Intensive treatment initiated in later adolescence
Number of subjects: 224
Study: 9707299

Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid mixture
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo mixture
Number of subjects: 15
Study: 8577212

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.a.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lansoprazole 45 mg b.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg b.i.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.i.d.
Number of subjects: 20
Study: 2225893

Group type: EXPERIMENTAL
Intervention: Nonabsorbable paste containing 2% tobramycin, 2% amphotericin B, and 2% polymyxin E applied locally to decontaminate the oropharynx.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Paste without antibiotics applied to the oropharynx (Control group).
Number of subjects: 28
Study: 371057

Group type: EXPERIMENTAL
Intervention: Clemastine, 1 mg/ml
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 10
Study: 28551060

Group type: EXPERIMENTAL
Intervention: Bupivacaine + Dexmedetomidine (100μg) in Group BD
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Bupivacaine in Group B
Number of subjects: 93

Group type: COMPARATOR
Intervention: Saline in Group C
Number of subjects: 93
Study: 27852903

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg/day)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Risedronate (35 mg/week)
Number of subjects: 171
Study: 24444658

Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) twice-daily (DUAL A1)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) once-daily (DUAL A2)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) twice-daily + PegIFN/RBV (QUAD B1)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) once-daily + PegIFN/RBV (QUAD B2)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Asunaprevir (200 mg) twice-daily + ribavirin (TRIPLE B3)
Number of subjects: 101
Study: 22362907

Group type: COMPARATOR
Intervention: Frequent hemodialysis (1.5‐2.75 hours, six times per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frequent hemodialysis (6‐8 hours, six times per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frequent hemodialysis (six sessions per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nocturnal hemodialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frequent hemodialysis
Number of subjects: 0
Study: 20063238

Group type: EXPERIMENTAL
Intervention: Zestra (topical botanical preparation)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 18280328

Group type: EXPERIMENTAL
Intervention: Six doses of activated charcoal (50 g each at 4-hour intervals)
Number of subjects: 4632

Group type: EXPERIMENTAL
Intervention: One dose of activated charcoal (50 g)
Number of subjects: 4632

Group type: COMPARATOR
Intervention: No activated charcoal
Number of subjects: 4632
Study: 15992199

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention in nursing homes
Number of subjects: 1169

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 1169
Study: 12687557

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg body weight) at weeks 0, 2, and 6
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10562681

Group type: EXPERIMENTAL
Intervention: Modified type III radical neck dissection (MRND)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Lateral neck dissection (LND)
Number of subjects: 132
Study: 8545692

Group type: EXPERIMENTAL
Intervention: Bolus fluid therapy
Number of subjects: 9

Group type: COMPARATOR
Intervention: No fluid
Number of subjects: 9

Group type: COMPARATOR
Intervention: Maintenance fluid
Number of subjects: 9
Study: 1878583

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX: 12 g/m2 as 4-hour infusion)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Intermediate-dose methotrexate (IDMTX: 1 g/m2 as 36-hour infusion)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation from HLA-compatible siblings
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with daily oral thioguanine and biweekly intravenous (IV) MTX
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Reprophylaxis to the CNS with IV/intrathecal (IT) MTX
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Risk factor analyses
Number of subjects: 130
Study: 6617676

Group type: EXPERIMENTAL
Intervention: Hydralazine (mean 127 mg/day, range 37-225)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 29889597

Group type: EXPERIMENTAL
Intervention: Brain-targeted treatment (BT) phase (left/right judgments and touch discrimination training)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care (education, strengthening, and stretching training)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No-treatment phase
Number of subjects: 10
Study: 30503111

Group type: EXPERIMENTAL
Intervention: D&C plus ACP gel
Number of subjects: 149

Group type: COMPARATOR
Intervention: D&C alone
Number of subjects: 149
Study: 27500951

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 28
Study: 24791578

Group type: EXPERIMENTAL
Intervention: Total energy intake (100-kcal increment)
Number of subjects: 8428

Group type: EXPERIMENTAL
Intervention: Substituting 5% of energy from fat by protein
Number of subjects: 8428

Group type: EXPERIMENTAL
Intervention: Substituting 5% of energy from carbohydrate by protein
Number of subjects: 8428
Study: 22290044

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injections
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (saline) injections
Number of subjects: 22
Study: 20080363

Group type: EXPERIMENTAL
Intervention: School-based substance abuse prevention program (12-hour curriculum)
Number of subjects: 7079

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 7079
Study: 18725699

Group type: EXPERIMENTAL
Intervention: Carrying a load of 10% or 20% of body weight with feet spaced shoulder width apart or together for 45 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carrying a briefcase, single strapped bag, or purse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standing with feet together (decreased base of support)
Number of subjects: 0
Study: 15965311

Group type: EXPERIMENTAL
Intervention: LY450139 (50 mg/day for 14 days)
Number of subjects: 37

Group type: COMPARATOR
Intervention: LY450139 (5 mg, 20 mg, 40 mg doses)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: LY450139 (50 mg/day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: LY450139 (all doses)
Number of subjects: 37
Study: 12810924

Group type: EXPERIMENTAL
Intervention: CsA + MTX
Number of subjects: 61

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 61
Study: 11086589

Group type: EXPERIMENTAL
Intervention: Arizona Pilot Project treatment (capitation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional care (fee-for-service)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various treatment administration sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pretreatment functional level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intercepts as predictors in structural models
Number of subjects: 0
Study: 9071904

Group type: EXPERIMENTAL
Intervention: Fenretinide (4-HPR) 200 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 24
Study: 7690396

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF) 5 micrograms/Kg/day
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 3521047

Group type: EXPERIMENTAL
Intervention: Omnipaque 300 (non-ionic contrast medium)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Rayvist 300 (ionic contrast medium)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both contrast media with optimal hydration
Number of subjects: 22
Study: 31880804

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) added to standard front-line chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) for patients with activating signaling mutations
Number of subjects: 0
Study: 29465434

Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of circulation-derived CD34+ cells (1.0 × 10 cells/each vessel; n = 18)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of circulation-derived CD34+ cells (3.0 × 10 cells/each vessel; n = 20)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of circulation-derived CD34+ cells
Number of subjects: 38
Study: 28012706

Group type: EXPERIMENTAL
Intervention: Methylphenidate (30mg single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26658988

Group type: EXPERIMENTAL
Intervention: Nereu Program (n = 54)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual counselling (n = 59)
Number of subjects: 113
Study: 23220098

Group type: EXPERIMENTAL
Intervention: Avonex
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CinnoVex
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 84
Study: 21823414

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 11

Group type: COMPARATOR
Intervention: Western medicine (Carbamazepine)
Number of subjects: 11
Study: 18292808

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 0
Study: 17262141

Group type: EXPERIMENTAL
Intervention: Etching with 10% hydrofluoric acid for 2 min (G1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etching with 10% hydrofluoric acid for 4 min (G2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50-microm particle aluminum oxide sandblasting for 5 s (G3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sandblasting followed by etching for 2 min (G4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sandblasting followed by etching for 4 min (G5)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control - no treatment (G6)
Number of subjects: 60
Study: 14586718

Group type: EXPERIMENTAL
Intervention: Candesartan (26 patients)
Number of subjects: 49

Group type: COMPARATOR
Intervention: ACE inhibitors (23 patients)
Number of subjects: 49
Study: 10618303

Group type: EXPERIMENTAL
Intervention: Reduced short-term scaling exponent alpha(1) <0.75
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Reduced alpha(1)
Number of subjects: 446
Study: 9127846

Group type: EXPERIMENTAL
Intervention: Extension-assisting brace
Number of subjects: 40

Group type: COMPARATOR
Intervention: Accelerated rehabilitation programme without brace
Number of subjects: 40
Study: 8459060

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (8.0 +/- 2.0 mg/liter)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30282349

Group type: EXPERIMENTAL
Intervention: Core stability exercises in addition to traditional treatment (infrared radiation and continuous ultrasound)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Traditional treatment (infrared radiation and continuous ultrasound)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Core stability exercises in addition to traditional treatment
Number of subjects: 34
Study: 29185931

Group type: EXPERIMENTAL
Intervention: J‐aggregated zeaxanthin dipalmitate formulation (10 mg free zeaxanthin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: H‐aggregated zeaxanthin dipalmitate formulation (10 mg free zeaxanthin)
Number of subjects: 16
Study: 26109247

Group type: EXPERIMENTAL
Intervention: PEERS program (treatment group, n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Delayed treatment control (control group, n = 10)
Number of subjects: 22
Study: 24415445

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 780
Study: 22264206

Group type: EXPERIMENTAL
Intervention: Individualized oral instruction
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Standardized oral instruction
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Written instruction
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 83
Study: 20440099

Group type: EXPERIMENTAL
Intervention: Resistance exercise-detraining group (RDT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Resistance exercise group (RT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 22
Study: 17524880

Group type: EXPERIMENTAL
Intervention: Enalapril (E) 10 mg/d, 15 patients
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Losartan (L) 50 mg/d, 20 patients
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Enalapril + Losartan (E+L) 10 mg/d + 50 mg/d, 13 patients
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no medication), 22 patients
Number of subjects: 70
Study: 16386523

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 26
Study: 12144582

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Famotidine 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9481855

Group type: EXPERIMENTAL
Intervention: Non-leukocyte-depleted blood products (NLD)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Leukocyte-depleted blood products (LD)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Comparison between NLD and LD groups
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: NLD patients without a history of previous transfusion
Number of subjects: 129
Study: 8535686

Group type: EXPERIMENTAL
Intervention: Prader orchidometer
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Takihara punched‐ring orchidometer
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Seager orchidometer
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ultrasonography (US)
Number of subjects: 31
Study: 2796623

Group type: EXPERIMENTAL
Intervention: Group A: 20 mL of 2% lidocaine + 3 mL normal saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group B: 20 mL of 2% lidocaine + 1:200000 epinephrine + 5 mL normal saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group C: 20 mL of 2% lidocaine + 2 mL of fentanyl + 3 mL normal saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group D: 20 mL of 2% lidocaine + 5 mL normal saline
Number of subjects: 60
Study: 266502

Group type: EXPERIMENTAL
Intervention: Monthly professional mechanical tooth cleaning
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control teeth (no cleaning during the study)
Number of subjects: 28
Study: 30817505

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus dexamethasone-soaked nasal packing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 60
Study: 29851985

Group type: EXPERIMENTAL
Intervention: RBV (Ribavirin) in combination with ombitasvir/paritaprevir/ritonavir and dasabuvir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RBV (Ribavirin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DAA treatment (ombitasvir/paritaprevir/ritonavir and dasabuvir)
Number of subjects: 0
Study: 27029846

Group type: EXPERIMENTAL
Intervention: Elvitegravir (reduced dose of 85 mg) co-administered with cobicistat and atazanavir
Number of subjects: 144

Group type: COMPARATOR
Intervention: Non-ritonavir-boosted atazanavir
Number of subjects: 144

Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir
Number of subjects: 144
Study: 24805892

Group type: EXPERIMENTAL
Intervention: Body weight‐supported treadmill plus overground walking practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home‐based exercise
Number of subjects: 0
Study: 21665549

Group type: EXPERIMENTAL
Intervention: Declines in lack of knowledge
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Declines in lack of control
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Declines in lack of time
Number of subjects: 213
Study: 19209185

Group type: COMPARATOR
Intervention: Paleolithic type diet
Number of subjects: 9
Study: 17629069

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg) thrice daily for 4 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 15059101

Group type: EXPERIMENTAL
Intervention: Oral nickel exposure (4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11454246

Group type: EXPERIMENTAL
Intervention: Annual mass treatment with single-dose diethylcarbamazine plus ivermectin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annual mass treatment with single-dose diethylcarbamazine plus ivermectin plus vector control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vector control
Number of subjects: 0
Study: 9736230

Group type: EXPERIMENTAL
Intervention: Calcium polycarbophil (0.62 g/twice daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7988625

Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol (1 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous butorphanol (1 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Transnasal butorphanol
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous and transnasal administration
Number of subjects: 48
Study: 2919094

Group type: EXPERIMENTAL
Intervention: Antiprostaglandin agents (naproxen)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Antiprostaglandin agents (pirprofen)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Antiprostaglandin agents (active treatment)
Number of subjects: 55
Study: 31227493

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Arthroscopic Partial Meniscectomy (APM)
Number of subjects: 321
Study: 30976844

Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 72
Study: 29017595

Group type: EXPERIMENTAL
Intervention: Locally produced enalapril (5-20 mg once daily for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imported enalapril (5-20 mg once daily for 14 days)
Number of subjects: 0